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Abstract 
Background: Over the last few decades the methylotrophic yeast Pichia pastoris has become a popular host for a 
wide range of products such as vaccines and therapeutic proteins. Several P. pastoris engineered strains and mutants 
have been developed to improve the performance of the expression system. Yield and quality of a recombinant prod-
uct are important parameters to monitor during the host selection and development process but little information is 
published regarding quality differences of a product produced by different P. pastoris strains.
Results: We compared titer and quality of several Nanobodies® produced in wild type and MutS strains. Titer in 
fed-batch fermentation was comparable between all strains for each Nanobody but a significant difference in quality 
was observed. Nanobodies expressed in MutS strains contained a product variant with a Δ−16 Da mass difference 
that was not observed in wild type strains. This variant showed substitution of methionine residues due to misincor-
poration of O-methyl-l-homoserine, also called methoxine. Methoxine is likely synthesized by the enzymatic action 
of O-acetyl homoserine sulfhydrylase and we confirmed that Nanobodies produced in the corresponding knock-out 
strain contained no methoxine variants. We could show the incorporation of methoxine during biosynthesis by its 
addition to the culture medium.
Conclusion: We showed that misincorporation of methoxine occurs particularly in P. pastoris MutS strains. This reduc-
tion in product quality could outweigh the advantages of using Mut strains, such as lower oxygen and methanol 
demand, heat formation and in some cases improved expression. Methoxine incorporation in recombinant proteins 
is likely to occur when an excess of methanol is present during fermentation but can be avoided when the methanol 
feed rate protocol is carefully designed.
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Background
The naturally occurring, heavy-chain only antibodies in 
Camelidae and their smaller derivatives called Nanobod-
ies have attractive properties over conventional antibod-
ies as therapeutics [1]. These structures lack the light 
chains of conventional antibodies and generally show 
better stability and solubility. Their ease in cloning and 
engineering allows the generation of constructs with a 
variety of avidity effects and bi- or multi-specificity. Nan-
obodies do not require the need for complex eukaryotic 
post-translation modifications, such as N-glycosylation, 
reducing the chance of unwanted heterogeneity and 
immunogenicity [2]. They can easily be expressed at lev-
els of more than 1 g  l−1 in fed-batch fermentation using 
micro-organisms. For therapeutic applications, immu-
noglobulins must be of very high product quality. This 
requires homogeneity in structural terms. Low yield and 
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lack of homogeneity will impact the economics of the 
production process and hence, the costs for the thera-
peutic overall. In recent years the methylotrophic yeast 
Pichia pastoris has received wide acceptance for the pro-
duction of biopharmaceuticals [3]. The success of the P. 
pastoris expression system is partly attributed to its abil-
ity to grow to high cell densities and as such increasing 
its volumetric productivity. In addition, P. pastoris uses 
a specific set of inducible enzymes to assimilate metha-
nol as the sole carbon and energy source. The first step in 
the methanol utilization (MUT) pathway is catalyzed by 
two alcohol oxidases (Aox1 and Aox2) that are strongly 
induced when P. pastoris is grown on methanol [4]. The 
promoter of the AOX1 gene has become a popular tool to 
drive the expression of recombinant proteins.
Several strains and mutants of P. pastoris are described 
and available. They can be used to manage specific issues 
such as proteolytic degradation or providing humanized 
N-linked oligosaccharide structures [5]. A specific type 
of strain has a deletion of the AOX1 gene, called MutS, 
and is commercially available from Invitrogen (KM71H), 
Graz University of Technology (CBS7435MutS) or Bio-
grammatics (BG11). MutS strains still express Aox2 
but grow slower than wild type strains when methanol 
is used as the sole carbon source. The slow growth and 
lower methanol consumption of MutS strains may have 
some advantages at large scale processes such as a lower 
demand for oxygen and reduced heat formation [6, 7]. 
In MutS strains the force of the Aox1 promoter can be 
directed mainly towards recombinant protein produc-
tion instead of using energy for Aox1 protein production. 
Nevertheless, most researchers use a wild type strain, 
although some researchers showed that MutS strains 
were advantageous for production [6, 8, 9].
The production process of a biological aims to achieve 
the highest possible product quality, nevertheless it is 
likely that small quantities of unwanted variants and 
product related impurities are present in the end prod-
uct. These include O-glycosylation, proteolytic degrada-
tion but also oxidation, carbamylation, deamidation and 
aggregation could occur due to specific upstream and 
downstream processes [10]. Strain differences or even 
clonal variations can also result in a difference in prod-
uct quality and heterogeneity. In this study, we compared 
the titer and quality of several Nanobodies expressed in 
wild type and in MutS strains. We observed an additional 
modification of Nanobodies when expressed in MutS 
strains due to amino acid misincorporation. We charac-
terized the nature of the modification via RPC-HPLC and 
ESI-Q-TOF MS. The plausible mechanism for the forma-
tion of this specific modification was further investigated 
and the effect of culture media and growth conditions 
explored.
Results and discussion
MutS versus wild type P. pastoris as a host for nanobody 
production
To evaluate which P. pastoris strain is most suitable for 
therapeutic Nanobody development we evaluated the 
titer and quality of three Nanobodies produced in sev-
eral wild type and MutS strains (Table 1). The strains were 
cultivated in 2  l fed-batch fermentations using a generic 
fermentation protocol. Fed-batches were performed with 
glycerol as carbon source followed by the methanol adap-
tation and induction phases. Because the MutS strains 
assimilate methanol more slowly than wild type, we 
extended the adaptation phase from 4 to 8  h, while the 
production phase continued for an additional 75  h. All 
three Nanobodies in this study are bivalent formats with 
a glycine–serine linker fusing the two variable domains 
together. Secretion of the Nanobody into the medium 
is controlled by the aMF secretion signal. The Nano-
bodies were purified using a proteinA cleanup step and 
expression level was determined by OD280 measurement. 
Table 1 Summary table of used strains, titers in fed-batch fermentation and the % Δ−16 Da variant
Nanobody productions were performed at 2 l scale, pH 6, 30 °C in complex medium with a methanol feed rate of 4 or 3 ml l−1 h−1 for wild type or MutS strains 
respectively. Except for a where the methanol feed rate was reduced to 0.5 ml l−1 h−1 in a co-feeding with sorbitol. Expression levels of Nanobodies were analyzed via 
a proteinA cleanup step followed by OD280 measurement. Relative abundance of the Δ−16 Da variant of the different Nanobodies was analysed via RP-HPLC followed 
by total mass measurement by ESI-Q-TOF-MS. The Δ−16 Da Nanobody variant was only observed in fed-batch fermentations with the MutS strains. A strong reduction 
of the Δ−16 Da was observed when the methanol feed rate was reduced to 0.5 ml l−1 h−1 and using co-feeding with sorbitol
Strain Genotype Source Nanobody A Nanobody B Nanobody C
Titers (g l−1) % Δ−16 Da 
variant
Titers (g l−1) % Δ−16 Da 
variant




AOX1 ARSa 5.2 0 7 0
CBS7435MutS aox1 [7] 4.5 4 10.5 (2.5)a 12 (0)a
X-33 AOX1 Invitrogen 6.4 0 9.1 0 0.9 0
KM71H (MutS) aox1 Invitrogen 1.2 8
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Depending on the Nanobody we observed similar expres-
sion levels in wild type and MutS strains (Table  1). The 
observed differences in titer between the strains for a 
particular Nanobody could be due to a difference in copy 
number of the Nanobody expression cassette. The qual-
ity was investigated by purifying the Nanobody via pro-
teinA followed by reverse phase high performance liquid 
chromatography (RP-HPLC) coupled to an ESI-Q-TOF 
mass spectrometer. The separation is based on difference 
in the hydrophobicity of the Nanobody and the product-
related variants, where the less hydrophobic proteins will 
elute earlier. Relative abundance of the Nanobody and its 
product-related variants is determined by comparing the 
integrated area of the peaks with the total integrated area. 
Figure 1 shows a typical RP-HPLC profile of a Nanobody 
and some product-related variants such as a variant with 
an oxidation and a variant with an O-glycosylation. Sur-
prisingly we observed an additional product-related vari-
ant of Δ−16 Da when the Nanobodies were expressed in 
MutS strains but not in wild type strains. An alternative 
feeding procedure using a mixed carbon source of meth-
anol and sorbitol reduced the presence of the Δ−16 Da 
variant significantly (Table 1). The Δ−16 Da variant was 
still detectable in MS but below the limit of quantifica-
tion using RP-HPLC analysis.
Identification of Δ−16 Da product‑related variant 
produced in MutS strains
LC–MS mass analyzer was employed to carry out MS/
MS and accurate mass analysis of the specific peptides 
in the Nanobody that contain the Δ−16  Da modifica-
tion. Nanobody B was produced in the MutS strain CBS-
7435MutS and contained up to 12  % of the Δ−16  Da 
variant. The Nanobody was purified and subjected to 
tryptic digest and subsequently analysed on LC–MS. A 
complex of 17 tryptic peptides was predicted covering 
the complete Nanobody sequence (Fig.  2). Nanobody 
B is a bivalent construct containing similar stretches in 
the sequence which sometimes results in the presence 
of twice the same peptide and consequently the same 
retention time on RP-HPLC. The Δ−16  Da variant was 
present in four peptides and, remarkably, all of them con-
tained a methionine residue, indicating that methionine 
could be the possible site of the Δ−16  Da modification 
(Fig. 2). This was confirmed by MS/MS fragmentation of 
the four peptides which showed that the Δ−16 Da modi-
fication was randomly distributed at the methionine resi-
dues of the Nanobody (see Additional file 1: Figure S1). 
Variants with more than one Δ−16 Da modification may 
be present at quantities lower than the detection limit of 
our equipment.
Fig. 1 A typical RP-HPLC profile of a Nanobody and product-related variants. Purified Nanobody C produced in the wild type strain X-33 or in the 
MutS strain KM71H, was analysed on a reversed phase HPLC system coupled to an ESI-Q-TOF mass spectrometer. Several modifications could be 
identified such as oxidation (Δ+16 Da) and hexose (Δ+162 Da). An additional and unknown Δ−16 Da variant was present when Nanobody C was 
expressed in the MutS strain KM71H and not in the WT strain X-33. Similar observations were done with Nanobody A and B (Table 1)
Page 4 of 9Schotte et al. Microb Cell Fact  (2016) 15:98 
peptides tryptic digest Nanobody B 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
retention time  
on RP-HPLC 
(minutes) 
unmodified 34.2   41.2 FT 32.6 FT 18.4 FT 48.4 29.8 30.9 FT 32.6 FT 18.4 FT 41.9 21.8 
∆-16 variant   39.8           47.7   28.4           40.6   
Peptides from tryptic digest Nanobody B 
Synthetic peptide10 modified with O-methyl-L-homoserine, 0.02 µg 
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Peptides from tryptic digest Nanobody B 
Synthetic peptide10 modified with Aspartic acid, 0.02 µg 
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Fig. 2 Identification of the Δ−16 Da modification as O-methyl-l-homoserine (methoxine) at methionine residues. a Tryptic digest of Nanobody B, 
produced and purified from the CBS7435MutS strain, generated 17 peptides. Retention times on RP-HPLC are indicated. Small peptides eluted in the 
flow through (FT). Four additional peptides were detected with a mass difference of −16 Da and showed a shorter retention time on RP-HPLC than 
their corresponding counterparts (peptides 2, 8, 10 and 16). These four peptides all contained a methionine residue. MS/MS fragmentation of the 
four peptides showed that the Δ−16 Da modification was located at the methionine (see Additional file 1: Figure S1); b and c Two possible amino 
acid substitutions resulting in a mass difference of Δ−16 Da were plausible: methionine → aspartic acid and methionine → O-methyl-l-homoser-
ine. Two synthetic peptides containing these substitutions were made and their behaviour compared on RP-HPLC to the corresponding Δ−16 Da 
of peptide ten that was generated after trypsin digest of Nanobody B. The peptide with incorporation of O-methyl-l-homoserine elutes at the same 
retention time of the peptide that contains the Δ−16 Da modification (28.4 min) whereas the peptide containing the aspartic acid substitution 
showed a shorter retention time of 25.0 min (c). * Aspecific tryptic cleavage product of peptide 8 (see Additional file 1: Figure S1C, D); ** unknown 
peptide
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Given the information that the Δ−16  Da is located 
at methionine residues we followed two hypotheses 
to identify the nature of this modification. Firstly, the 
misincorporation of aspartate for methionine fits a dif-
ference of Δ−16 Da. However, this is an unusual event 
not previously described and difficult to relate to the 
MutS phenotype. Secondly, Δ−16 Da is the exact mass 
difference between oxygen and sulphur. Changing 
the sulphur atom in methionine to oxygen generates 
O-methyl-l-homoserine also called methoxine. The 
accumulation of methoxine was previously demon-
strated in several methylotrophic bacteria [11]. There-
fore it is plausible that P. pastoris synthesizes methoxine 
during the induction phase when methanol is added. 
Moreover, Murooka et  al. showed that the enzyme 
O-acetyl homoserine sulfhydrylase from Saccharomyces 
cerevisiae, which operates in the methionine biosynthe-
sis pathway, can synthesise O-alkyl-l-homoserine from 
alcohols and O-acetyl-l-homoserine [12]. To analyse 
both hypotheses we used two synthetic peptides con-
taining either an aspartic acid or a methoxine at the 
original methionine position of one of the peptides gen-
erated from the tryptic digest of Nanobody B (Fig. 2b). 
Due to the significant differences in hydrophobicity the 
two peptides will behave differently on RP-HPLC versus 
the methionine containing peptide. The overlay of UV 
214  nm chromatograms shows that the peptide with 
methoxine incorporation elutes at the same retention 
time of the peptide that contains the Δ−16  Da modi-
fication (28.4  min) whereas the peptide containing the 
aspartic acid substitution is less hydrophobic resulting 
in a shorter retention time of 25.0  min on the column 
(Fig.  2c). These observations strongly suggest that the 
Δ−16 Da modification is the result of methoxine misin-
corporation at methionine residues.
Mechanism of methoxine incorporation in P. pastoris
The methionine biosynthetic pathways of bacteria, yeast, 
and plants are identical up to homoserine and from 
homocysteine to methionine. However, from homoser-
ine to homocysteine, the pathways differ in a number 
of aspects [13]. An important variation is the sulphur 
atom assimilation into the methionine backbone. There 
are two alternative routes: the first is the transsulfuryla-
tion pathway and the second the sulfhydrylation path-
way. The transsulfuration pathway uses cysteine as the 
sulfur donor to incorporate into O-acetyl homoserine 
to form cystathionine. In the second route, the sulfur 
donor is sulfide, which is incorporated into O-acetyl 
homoserine by O-acetyl homoserine sulfhydrylase to 
form homocysteine. This direct sulfhydrylation path-
way is found in yeast such as S. cerevisiae and most 
likely used in P. pastoris as well [14]. As mentioned in 
the above chapter the research of Murooka et al. gave us 
an important clue that the enzyme O-acetyl homoserine 
sulfhydrylase may be directly involved in the generation 
of methoxine in P. pastoris. A scheme detailing the role 
of O-acetyl homoserine sulfhydrylase and how incorpo-
ration of methoxine in proteins may occur is shown in 
Fig. 3. The assembly of methoxine into proteins reflects 
the imperfect selectivity of the methionyl-tRNA syn-
thetase for methionine. This has been demonstrated 
previously for several analogues of methionine such as 
selenomethionine and telluromethionine [15], norleu-
cine [16], trifluoromethionine [17] and ethionine [18]. 
To our knowledge the translational activity of methox-
ine has not been previously demonstrated in  vivo. The 
fact that MutS strains are more susceptible to methoxine 
incorporation makes sense because the deletion of the 
AOX1 gene results in lower methanol assimilation and 
possibly to higher intracellular methanol concentrations 
than in wild type strains. In the excess of methanol the 
intracellular concentration of methoxine might increase 
even further because the synthesis from its precursor 
O-acetyl homoserine only involves a single enzymatic 
step whereas the formation of methionine from the same 
precursor involves a two-step enzymatic process. In 
addition, induction of high Nanobody expression levels 
places a large demand for methionine on the cell which 
may result in a depletion of methionine and increased 
expression of the methionine biosynthetic enzymes such 
as O-acetyl homoserine sulfhydrylase, further increasing 
methoxine formation. It remains unclear if the formation 
of methoxine by the enzyme O-acetyl homoserine sulf-
hydrylase is physiologically relevant such as to remove 














Fig. 3 Model of methoxine incorporation in P. pastoris. Promiscuity 
of O-acetyl homoserine sulfhydrylase for H2S and methanol. Dashed 
arrows show the steps leading to the production of methoxine and 
subsequent incorporation into the proteome of P. pastoris
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Controlling the methoxine incorporation
To illustrate the dependency of methanol for the for-
mation and incorporation of methoxine we analysed 
methoxine incorporation when glycerol or metha-
nol was used as carbon source (Fig.  4). Therefore, the 
expression of Nanobody B was placed under the con-
trol of a constitutive Gap promoter. As expected, using 
the MutS strain KM71H as host, a significant amount 
of methoxine incorporation could be observed when 
methanol was used as carbon source. In contrast, using 
glycerol as carbon source we did not observe any meth-
oxine incorporation, which illustrates the dependency 
of methanol in methoxine biosynthesis. Surprisingly, 
we observed a small amount of methoxine incorpora-
tion using the wild type strain X-33, but again, only 
when methanol was used as carbon source (Fig.  4). 
Although we never observed methoxine incorporation 
in Nanobodies using wild type P. pastoris in fed-batch 
fermentation, we consistently did so when expression 
was performed in shake flask. We believe this is related 
to the spiked and uncontrolled addition of methanol 
in shake flask whereas in fed-batch fermentation the 
methanol feed rate is controlled by monitoring the dis-
solved oxygen of the culture. This illustrates the impor-
tance of optimizing the methanol feed protocol to 
provide high product quality.
To show the translational activity of methoxine we 
added methoxine to the medium of cells that consti-
tutively expressed Nanobody B (Fig.  5). To prevent the 
incorporation of endogenous produced methoxine we 
used glycerol as carbon source. We observed that over 
10  % of Nanobody B had incorporated the exogenous 
supplemented methoxine. Similar levels of methoxine 
incorporation were observed in both wild type and MutS 
strains. These results support the idea that the mecha-
nism of methoxine incorporation follows the route of 
mischarged methionyl-tRNAMet and subsequent incor-
poration into proteins. Mischarging of methionyl-
tRNAMet and consequent misincorporation of norleucine 
has been described frequently during recombinant pro-
tein production in Escherichia coli [16, 19]. The incor-
poration of norleucine into peptides is the result of the 
inadequate substrate specificity of methionyl-tRNA syn-
thases and evading the translational proofreading activi-
ties [20]. Norleucine can substitute for methionine at 
random positions in proteins which is in agreement with 
our observations of methoxine incorporation [21]. These 
misincorporations can be suppressed by addition of 
methionine into the medium. To evaluate if supplemen-
tation of methionine to the P. pastoris medium could also 
prevent methoxine incorporation we performed shake 
flask experiments with the MutS strain CBS7435MutS 
expressing Nanobody B (Fig. 5). The Nanobody produc-
tion was initiated by switching the cells into methanol 
containing medium with or without methionine. The 
highest dose of methionine (400  mg  ml−1) resulted in 
a fivefold decrease in methoxine incorporation. Sup-
plementation of methionine every 12  h after induction 
prevented the methoxine incorporation completely. The 
level of methoxine incorporation was significantly lower 
in shake flask than in fed-batch fermentation (2.5 versus 
12 % respectively). This could be related to the higher cell 
density in fermentation versus shake flask (OD600 = 400 























Fig. 4 Exogenous supplied methoxine is incorporated in vivo and 
acts as a metabolic analogue of methionine in P. pastoris. Nanobody B 
was produced under the control of the constitutive Gap promoter in 
the wild type X-33 strain and in the KM71H strain (MutS). Expressions 
were performed in shake flasks. Methoxine was added to the medium 
every 8 h (200 mg l−1) over a 48 h period. Relative abundance of the 
Δ−16 Da variant was done via RP-HPLC analysis followed by total 

















- 200 400 4x400 
methionine (mg.l-1) 
Fig. 5 Methionine supplementation reduces the amount of 
the methoxine incorporation. Nanobody B was produced in the 
CBS7435MutS strain in shake flasks. Methionine was added at the 
indicated concentration when cells were switched to methanol con-
taining medium. In one condition (4 × 400) a methionine concentra-
tion of 400 mg ml−1 was added four times (every 12 h after the cells 
were switched to methanol containing medium). Relative abundance 
of the Δ−16 Da variant was done via RP-HPLC analysis followed by 
total mass measurement by ESI-Q-TOF-MS. Expression was verified on 
SDS-PAGE and Coomassie staining
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To illustrate the role of the enzyme O-acetyl homoser-
ine sulfhydrylase in the production of methoxine we 
knocked-out the enzyme in the strain CBS7435MutS 
expressing Nanobody B. The cells were grown in rich 
media containing yeast extract and peptone to balance 
the methionine auxotrophy. The control strain produced 
0.9 ± 0.17 % methoxine variant of Nanobody B whereas 
the knock-out strain showed a complete absence of 
methoxine incorporation as analysed on RP-HPLC/MS 
(Table 2). This observation clearly point towards the cen-
tral role of O-acetyl homoserine sulfhydrylase in the for-
mation of methoxine in P. pastoris.
Conclusions
In this study we observed a new product related variant 
with a mass difference of Δ−16 Da. The modification was 
identified as the misincorporation of O-methyl-l-ho-
moserine (also called methoxine) at methionine residues. 
Because several P. pastoris produced biopharmaceutical 
products have been approved for human use, one would 
expect to find earlier reports describing this modifi-
cation. However, most researchers probably use wild 
type P. pastoris strains, which, as we demonstrated, are 
less likely to incorporate methoxine. Some studies have 
shown MutS strains to be superior over wild type strains 
in terms of recombinant protein production [6]. In case a 
MutS strain would be favourable than the wild-type strain 
it is important to monitor methoxine incorporation and 
optimize a methanol feed strategy accordingly. However, 
we showed that it is not impossible to have small quan-
tities of methoxine incorporation by wild-type P. pasto-
ris as well. Similar to other post-translationally modified 
proteins, methoxine containing proteins could elicit an 
immune response in humans. A proper balance between 
amino acid synthesis and protein synthesis would keep 
any detrimental effects of methoxine formation within 
acceptable limits. We have not investigated if the replace-
ment of methionine with methoxine affects the activ-
ity of Nanobodies. This may depend on the position of 
the methionine residue or may not affect the activity at 
all as described for the replacement of methionine with 
norleucine in several enzymes [22, 23]. Methionine-
rich proteins that are overproduced in P. pastoris using 
methanol as sole carbon source are probably more likely 
to be contaminated with methoxine residues. A purifi-
cation protocol that removes all methoxine containing 
variants could be a difficult and costly process. Supple-
mentation of the cultivation media with methionine 
could be an elegant method to produce proteins free of 
methoxine. The addition of methionine also represses the 
synthesis of the enzymes involved in methionine metabo-
lism, including O-acetyl homoserine sulfhydrylase [24]. 
A genetic approach to prevent methoxine synthesis and 
incorporation could be the deletion of genes involved in 
the biosynthesis of methionine and methoxine such as 
we demonstrated with the O-acetyl homoserine sulfhy-
drylase knock-out. A straightforward way to avoid the 
methoxine issue is the use of methanol independent pro-
moters such the constitutive Gap promoter, the recently 
developed “methanol-independent” Aox1 promoter 
variants [25] or glucose-limit inducible promoters [26]. 
Finally, it is well known that the growth speed of a MutS 
strain is slower than the wild type strain when grown on 
methanol. This has always been attributed to the slower 
methanol assimilation but it cannot be ruled out that this 
is actually to be attributed to methoxine incorporation 
into the proteome.
Methods
Strains, strain construction and vectors
Pichia pastoris strains used and constructed during this 
study are based on the wild-type strain CBS7435 (NRRL-
Y11430, ATCC 76273) and described in Table  1. The 
strain CBS7435MutS was engineered and described by 
Näätsaari et  al. [7]. Recombinant DNA manipulations 
were performed using the Top10 E. coli strain (Invitrogen 
Corp., Carlsbad, CA) according to standard protocols. All 
three Nanobody constructs were bivalent construct that 
linked two different Nanobody building blocks together 
with a 9GS linker. Pichia pastoris competent cells were 
Table 2 Methoxine incorporation in the MutS and O-acetyl homoserine sulfhydrylase knock-out strains
Nanobody B was produced in the CBS7435MutS and in the CBS7435MutS strain with an inactivation of O-acetyl homoserine sulfhydrylase gene (CBS7435MutSΔOAHS) 
in shake flasks using complex media. Titers of Nanobody B were analyzed via a proteinA cleanup step followed by OD280 measurement. Relative abundance of the 
methoxine variant was analysed via RP-HPLC followed by total mass measurement by ESI-Q-TOF-MS. The methoxine variant of Nanobody B was only produced in the 
MutS strain and absent when O-acetyl homoserine sulfhydrylase was inactivated. Experiments were performed in triplicate
Strain Genotype Source Nanobody B
Titers (g l−1) % Δ−16 Da 
variant
CBS7435MutS aox1 [7] 2.4 ± 0.7 0.90 ± 0.17
CBS7435MutSΔOAHS aox1 met25 This study 2.1 ± 0.2 0
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prepared and transformed by electroporation as previ-
ously described [27]. Transformation of P. pastoris was 
done using 2  μg BsiWI linearized plasmid DNA har-
boring the Nanobodies expression cassettes of inter-
est. Transformations were selected on YPD agar plates 
supplemented with 500  mg  l−1 zeocin. Pichia pastoris 
strain CBS7435MutS was transformed with Nanobod-
ies cloned in pPpT4_Alpha_S vector [7]. Other P. pasto-
ris strains were transformed with Nanobodies cloned in 
the pPicZalpha or pGAPZa vector (Invitrogen). Secre-
tion of the Nanobodies was achieved by fusion to the 
prepro-signal sequence of the S. cerevisiae alpha mating 
factor. The gene coding for O-acetyl homoserine sulfhy-
drylase (CAY71572.1), designated Met25, was disrupted 
in the strain CBS7435MutS expressing Nanobody B by 
gene inactivation through single homologous recom-
bination. The knock-in vector was generated contain-
ing the last 107 base pairs of the promoter followed by 
the coding sequence of O-acetyl homoserine sulfhy-
drylase corresponding to the protein sequence of Met1 
to Lys147. An additional base pair was inserted in the 
coding region of Pro2 (cct →  cgct) which introduced a 
frameshift to prevent synthesis of a truncated O-acetyl 
homoserine sulfhydrylase. The gene fragment was syn-
thesized using gBlocks® (Integrated DNA Technolo-
gies, Inc.), amplified using the FW and RV primer set 
ATTATAGATCTTCAACATTGAAACCCCTCG and TC 
AGAAAGATCTTTATCACTTGGTCTTATCATCG and 
cloned via BglII into a vector carrying blasticidin resist-
ance. The vector was linearized using the unique BamHI 
site in the gene fragment and transformed to the CBS-
7435MutS expressing Nanobody B. Clones with an inac-
tivated O-acetyl homoserine sulfhydrylase gene were 
selected as described previously [28] and disruption of 
the gene was confirmed by PCR using the primer couple 
CCTTGCCGCATCACGTGACCCGAT which is located 
upstream of the promoter of the O-acetyl homoserine 
sulfhydrylase gene and GGATTGGGTGTGATGTAAGG 
ATTC located on the backbone of the knock-out vector.
Cultivations
Single colonies were transferred to 5  ml falcon tubes 
for standard cultivation as described previously [7]. 
The cells were cultivated for 2  days and 25  µl metha-
nol was added to the culture in the morning and even-
ing to maintain induction. The supernatant was then 
harvested and analyzed on NuPage Bis-Tris Gel (Life 
Technologies). The culture conditions in shake flasks 
for the experiment that included the P. pastoris strain 
with an inactivated O-acetyl homoserine sulfhydrylase 
were done at 30  °C in 5  ml of BGCM medium (5  g/l 
yeast extract, 10  g/l peptone, 10  % glycerol, 13.4  g/l 
YNB, 0.4  mg/l D-Biotine, 0.1  M potassium phosphate 
buffer pH 6). Cells were harvested by centrifugation 
and resuspended in 5  ml of BMCM medium which is 
the same as BGCM with 0.5  % (v/v) methanol instead 
of glycerol. The cells were cultivated for 2 days and 25 µl 
methanol was added to the culture in the morning and 
evening to maintain induction. Fed-batch cultivation 
were performed at 2 l scale as previously described [29]. 
The methanol adaptation phase for wild type strains was 
stepwise using a methanol feed rate of 1.5 ml l−1 h−1 for 
the first 2  h; 3  ml  l−1  h−1 for the next 2  h followed by 
a feed rate at 4 ml  l−1 h−1 till end of fermentation. For 
MutS strains the stepwise methanol adaptation phase 
was from 0 to 2 h at 1 ml l−1 h−1 followed by a feed rate 
at 3  ml  l−1  h−1 till end of fermentation. Mixed feed-
ing was performed during the induction phase using 
0.5  ml  l−1  h−1 methanol with 4.75  g  l−1  h−1 of a 60  % 
(w/v) sorbitol solution.
Chemicals
Enzymes were purchased from New England Biolabs 
and trypsin from Promega. Difco™ yeast nitrogen base 
without amino acids (YNB), HypA peptone was obtained 
from BioSpringer and yeast extract from Oxoid. Glucose 
was obtained from Merck chemicals, glycerol from VWR 
chemicals, sorbitol and D-Biotin from Sigma Aldrich. 
Select agar and Zeocin™ were obtained from Invitrogen. 
Methoxine (O-methyl-l-homoserine) was supplied by 
IRIS Biotech GmbH and methionine ordered at Sigma-
Aldrich. Synthetic peptides were ordered at Bachem.
Analysis
ProteinA cleanup was performed using MabSelect 
Xtra resin (GE Healthcare). Briefly clarified broth 
sample was centrifuged to remove any remaining par-
ticulate matter. The sample was applied on the column 
according to the manufacturer’s instructions. The col-
umn was washed with six column volumes of D-PBS 
buffer before elution with 1  ml of 0.1  % TFA. Based 
on the protein concentration obtained by UV absorb-
ance (Jasco V-650), approximately 4 μg of each elution 
sample was analyzed on RP-HPLC/MS. The presence 
of Nanobody related variants was analyzed using a 
Reversed Phase HPLC system (Agilent) coupled to an 
ESI-Q-TOF mass spectrometer. Relative abundance of 
variants was performed on baseline to valley integra-
tion. Trypsin digest of Nanobody B was performed with 
1:25 of Trypsin: Nanobody (w:w) and 0.1 % Rapigest in 
100  mM Tris-HCl pH 7.5 and incubated at 37  °C. Of 
this digest 7.5 μg was applied on an Acquity UPLC BEH 
column from Waters combined with Agilent Q-TOF to 
perform the MS/MS analysis.
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